2022 Year in Review: Litigation
Our return to office in 2022 coincided with a year of intense activity in our dispute resolution engagements and other areas of the practice. Wins at trial...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Dr. Andrew Tepperman is a vice president in CRA’s Life Sciences Practice. Dr. Tepperman has over two decades of experience assisting clients with high-stakes economic and damages issues in intellectual property, antitrust, and government litigation, and international arbitration.
In intellectual property disputes, Dr. Tepperman advises clients on damages in patent and trade secret matters and assesses commercial success and irreparable harm. Across a range of antitrust assignments, he has regularly evaluated market power and competitive effects associated with various types of conduct, including patent settlement agreements, vertical restraints, price-fixing, and claims based on the use of intellectual property rights. His government engagements have addressed economic and industry issues in fraud, nuisance, and regulatory lawsuits, along with tax and transfer pricing disputes. In breach of contract matters, he has analyzed business and economic considerations relevant to contract performance as well as damages.
Dr. Tepperman’s practice has an emphasis on clients in the life sciences sector, including pharmaceutical, biologic, device, and diagnostic companies. He also has extensive experience addressing damages and further economic issues for clients in the technology sector and other industries. Dr. Tepperman has served as a testifying expert in matters before Canadian, US, and UK courts, and has testified at trial on multiple occasions. He has advised clients on matters before regulatory agencies, including the Canadian Competition Bureau.
Dr. Tepperman joined CRA in 2001, upon completing his PhD in economics from the University of Toronto. His doctoral dissertation focused on the strategic use by companies of intellectual property rights and economic implications of that use.